KLK3 and cancer: In a recent analysis of the Dana-Farber Cancer Institute (DFCI) 95-096 trial, only 29 of 108 men (26.9%) who experienced PSA failure died of prostate cancer at a median follow-up of 16.6 (interquartile range [IQR], 15.4-17.7) years.7 Furthermore, a recent meta-analysis from the Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP) working group reported that PSA event–free survival exhibited a weak association with overall survival.8